Latest Conference Coverage


Concomitant Atogepant and Ubrogepant for Acute and Preventive Migraine Demonstrates Safety

Concomitant Atogepant and Ubrogepant for Acute and Preventive Migraine Demonstrates Safety

April 15th 2024

Combination of atogepant and ubrogepant resulted in minimal adverse events, and were safe and well-tolerated over a 12-week period.


Bruce Bebo, PhD

Recognizing Excellence in Multiple Sclerosis Research, the Dystel Prize: Bruce Bebo, PhD

April 15th 2024

The executive vice president of research at National MS Society talked about the Dystel Prize which is presented at AAN to a recognized individual who promotes further advancements in understanding and treating MS. [WATCH TIME: 3 minutes]


Long-Term Atogepant Effective, Safe as Migraine Preventive, Open-Label Studies Show

Long-Term Atogepant Effective, Safe as Migraine Preventive, Open-Label Studies Show

April 15th 2024

Results showed consistent reductions in monthly migraine days over 48 weeks, with a favorable safety profile observed.


Susan W. Broner, MD

Understanding Headache Essentials for General Neurologists: Susan W. Broner, MD

April 15th 2024

The medical director of the Weill Cornell Medicine Headache Program discussed key essential knowledge on the diagnosis, treatment, and pathophysiology of different headache types. [WATCH TIME: 6 minutes]


Jacob Pellinen, MD

Cenobamate's Efficacy in Drug-Resistant Epilepsy: Jacob Pellinen, MD

April 14th 2024

The assistant professor of neurology at University of Colorado School of Medicine discussed findings on the impact of cenobamate on hospital visits and emergency care for patients with drug-resistant epilepsy following surgery. [WATCH TIME: 3 minutes]


Thomas F. Scott, MD

New Insights into BTK Inhibitors and MRI Techniques for Smoldering MS: Thomas F. Scott, MD

April 14th 2024

The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]


Extended Use of Investigational Agent IPX203 Safe in Parkinson Disease

Extended Use of Investigational Agent IPX203 Safe in Parkinson Disease

April 14th 2024

Even at the highest modal dose range, findings from the phase 3 RISE-PD trial showed that IPX203 did not increase safety risks for patients with Parkinson disease over time.


Jina Swarz, MD, PhD

Pridopidine Maintains Effectiveness in Huntington Disease Without Antidopaminergic Medications

April 14th 2024

New findings from the phase 3 PROOF-HD trial showed that pridopidine outperformed placebo up to 78 weeks in patients with Huntington disease even after excluding those on neuroleptics and antichorea medications.


Riliprubart Demonstrates Favorable Benefit-Risk Profile as Potential Treatment for Chronic Demyelinating Polyneuropathy

Riliprubart Demonstrates Favorable Benefit-Risk Profile as Potential Treatment for Chronic Demyelinating Polyneuropathy

April 13th 2024

Patients on riliprubart demonstrated improvements on several measures of disability and impairment, including the INCAT, I-RODS, MRC-SS, and grip strength.


Earlier Initiation of Ublituximab Results In Improved Disease Outcomes in Treatment-Naïve Multiple Sclerosis

Earlier Initiation of Ublituximab Results In Improved Disease Outcomes in Treatment-Naïve Multiple Sclerosis

April 13th 2024

Patients with first MS symptoms less than 3 years prior to enrollment saw greater long-term benefits with ublituximab than those with longer disease course.


Pooled Phase 3 Studies Highlight AXS-07 as Effective Migraine Treatment

Pooled Phase 3 Studies Highlight AXS-07 as Effective Migraine Treatment

April 13th 2024

In the phase 3 MOMENTUM and INTERCEPT studies, patients treated with AXS-07 saw reductions in headache pain freedom, most bothersome symptoms, and use of rescue medications.


Krystyn J. Van Vliet, PhD & Anna Jagielska, PhD, MSc

Bridging Engineering and Neuroscience in the Creation of Artificial Axons for Myelination Research: Krystyn J. Van Vliet, PhD & Anna Jagielska, PhD, MSc

April 11th 2024

The professor of materials science and engineering at Cornell University and chief executive officer at Artificial Axon Labs talked about the development of artificial axons through 3D printing. [WATCH TIME: 6 minutes]


Shiv Saidha, MBBCh

Reevaluating Neuroprotective Multiple Sclerosis Trial Designs Using the Visual System: Shiv Saidha, MBBCh

April 8th 2024

The professor of neurology at Johns Hopkins Medicine discussed the trial design of the phase 4 RENEW study assessing the long-term safety profile of mitoxantrone in multiple sclerosis. [WATCH TIME: 9 minutes]


Marjan Gharagozloo, PhD

The Potential of NLRX1 in Immune Regulation and Neuroprotection for Inflammatory Neurodegenerative Disorders: Marjan Gharagozloo, PhD

April 7th 2024

The assistant professor of neurology at Johns Hopkins Medicine talked about her preclinical research in immunology to explore the intricate mechanisms controlling chronic inflammation in the central nervous system. [WATCH TIME: 5 minutes]


Marcello Paglione, PhD

Givinostat's Multifactorial Mechanism of Action in Duchenne Muscular Dystrophy: Marcello Paglione, PhD

April 5th 2024

The executive medical lead at Italfarmaco SpA expressed his confidence in givinostat to mitigate the progression of Duchenne muscular dystrophy, emphasizing its multifactorial mechanism of action. [WATCH TIME: 5 minutes]


Shiv Saidha, MBBCh

Targeting Neurodegeneration to Impart Neuroprotection in Progressive MS: Shiv Saidha, MBBCh

April 4th 2024

The professor of neurology at Johns Hopkins Medicine discussed the limited impact of current therapies on retinal atrophy rates in progressive multiple sclerosis at the 2024 ACTRIMS Forum. [WATCH TIME: 5 minutes]


Marcello Paglione, PhD

Evaluating Givinostat's Efficacy and Safety in Duchenne Muscular Dystrophy: Marcello Paglione, PhD

April 3rd 2024

The executive medical lead at Italfarmaco SpA talked about data from both animal models and clinical trials supporting the efficacity of givinostat in patients with Duchenne muscular dystrophy at MDA 2024. [WATCH TIME: 5 minutes]


Aki Ko, chief executive officer at Elixirgen Therapeutics

Elixirgen Therapeutics’ Bobcat mRNA Therapeutic for Duchenne Muscular Dystrophy: Aki Ko

March 28th 2024

The chief executive officer at Elixirgen Therapeutics discussed the company’s mRNA as a promising therapeutic avenue for Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]


Le Hua, MD

Analyzing Cognitive Profiles in Multiple Sclerosis and Alzheimer Disease: Le Hua, MD

March 27th 2024

The director of the Multiple Sclerosis Program at the Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed findings from a study that compared cognitive profiles between patients with multiple sclerosis and Alzheimer disease. [WATCH TIME: 5 minutes]


Amanda Peltier, MD

Integrating Genetics and Transitional Support in Muscular Dystrophy Care: Amanda Peltier, MD

March 27th 2024

The professor of neurology at Vanderbilt University Medical Center discussed advocating for reinstating personalized resources, expanding genetic testing, and improving transitional care in muscular dystrophy. [WATCH TIME: 5 minutes]


Promising Preclinical Evidence of Skeletal Muscle Regenerator SAT-3247: Frank Gleeson

Promising Preclinical Evidence of Skeletal Muscle Regenerator SAT-3247: Frank Gleeson

March 26th 2024

The president and chief executive officer of Satellos Bioscience provided an overview of the previously observed preclinical data supporting SAT-3247 as a potential therapy for muscular dystrophies. [WATCH TIME: 4 minutes]


Justin Moy

A Patient Perspective on Gene Therapy for Neuromuscular Diseases: Justin Moy

March 26th 2024

The second-year PhD student in bioinformatics at Boston University who lives with LAMA2 congenital muscular dystrophy talked about the potential impact and challenges of gene therapy in neuromuscular diseases. [WATCH TIME: 5 minutes]


Amanda Peltier, MD

Enhancing Multidisciplinary Care for Neuromuscular Disorders: Amanda Peltier, MD

March 25th 2024

The professor of neurology at Vanderbilt University Medical Center talked about the importance of multidisciplinary care centers to improve accessibility and quality of care for patients with neuromuscular disorders. [WATCH TIME: 5 minutes]


Marjan Gharagozloo, PhD

Targeting the NLRX1 Pathway for Neuroprotection in Multiple Sclerosis: Marjan Gharagozloo, PhD

March 25th 2024

The assistant professor of neurology at Johns Hopkins Medicine talked about recent research that suggests activating the NLRX1 pathway could offer neuroprotection in multiple sclerosis. [WATCH TIME: 5 minutes]


 Jeffrey Huang, PhD

Therapeutic Avenues for Multiple Sclerosis Through Immune Cell Communication: Jeffrey Huang, PhD

March 24th 2024

The associate professor of biology at Georgetown University talked about how immune cells can communicate with brain cells to enhance repair processes, which may offer potential treatment targets for multiple sclerosis. [WATCH TIME: 5 minutes]


Clinical Benefits to Emphasizing Patient Voices in ALS: Brooke Eby

Clinical Benefits to Emphasizing Patient Voices in ALS: Brooke Eby

March 22nd 2024

A patient advocate within the ALS community discussed the importance of incorporating patients and their voices into clinical meetings and trial design to ultimately meet treatment goals. [WATCH TIME: 4 minutes]


Overviewing Phase 2 SYNAPSE-SMA Trial of NMD670 for Spinal Muscular Atrophy: Jorge Quiroz, MD, MBA

Overviewing Phase 2 SYNAPSE-SMA Trial of NMD670 for Spinal Muscular Atrophy: Jorge Quiroz, MD, MBA

March 22nd 2024

The chief medical officer of NMD Pharma provided perspective on a newly launched phase 2 study assessing NMD670, a first-in-class neuromuscular transmission enhancer, in patients with spinal muscular atrophy type 3. [WATCH TIME: 5 minutes]


Episode 111: Reviewing ACTRIMS 2024

Episode 111: Reviewing ACTRIMS 2024

March 22nd 2024

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 32 minutes]

© 2024 MJH Life Sciences

All rights reserved.